Patient‐related characteristics associated with non‐persistence with statin therapy in elderly patients following an ischemic stroke

Purpose This study was aimed at evaluating the extent of non‐persistence with statin therapy in elderly patients after an ischemic stroke and identifying patient‐related characteristics that are risk factors for non‐persistence. Methods The evaluable study cohort (n = 2748) was derived from the data...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacoepidemiology and drug safety 2017-02, Vol.26 (2), p.201-207
Hauptverfasser: Wawruch, Martin, Zatko, Dusan, Wimmer, Gejza, Luha, Jan, Hricak, Vasil, Murin, Jan, Kukumberg, Peter, Tesar, Tomas, Hloska, Adam, Shah, Rashmi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 207
container_issue 2
container_start_page 201
container_title Pharmacoepidemiology and drug safety
container_volume 26
creator Wawruch, Martin
Zatko, Dusan
Wimmer, Gejza
Luha, Jan
Hricak, Vasil
Murin, Jan
Kukumberg, Peter
Tesar, Tomas
Hloska, Adam
Shah, Rashmi
description Purpose This study was aimed at evaluating the extent of non‐persistence with statin therapy in elderly patients after an ischemic stroke and identifying patient‐related characteristics that are risk factors for non‐persistence. Methods The evaluable study cohort (n = 2748) was derived from the database of the largest health insurance provider in the Slovak Republic. Patients aged ≥65 years who were initiated on statin therapy following the diagnosis of an ischemic stroke during one full year (1 January 2010 to 31 December 2010) constituted this cohort. Each patient was followed for a period of 3 years from the date of the first statin prescription. Patients with a continuous treatment gap of 6 months without statin prescription were designated as non‐persistent. The Cox proportional hazard model was applied to determine patient‐associated characteristics that influenced the likelihood of non‐persistence. Results During the 3‐year follow‐up period, 39.7% of patients in the study cohort became non‐persistent. Factors associated with decreased probability of a patient becoming non‐persistent were age ≥75 years (hazard ratio (HR) 0.75), polypharmacy (concurrent use of ≥6 drugs) (HR 0.79), diabetes mellitus (HR 0.80), dementia (HR 0.81) and hypercholesterolemia (HR 0.50). On the other hand, the presence of anxiety disorders (HR 1.33) predicted an increased likelihood of a patient being non‐persistent. Conclusions Our findings suggest that patients aged ≥75 years or those with the presence of diabetes mellitus, dementia, hypercholesterolemia or polypharmacy were likely to be persistent with statin therapy, whereas those with anxiety disorders may need greater assistance with persistence of statin therapy. Copyright © 2016 John Wiley & Sons, Ltd.
doi_str_mv 10.1002/pds.4148
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1868316003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1847892642</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3498-6ca3dcaf8289c49df010625e90c0446f78ed4e44763e096d61cceb808b07e983</originalsourceid><addsrcrecordid>eNqNkb9u2zAQxokiReMmBfIEAYEsXeSQIkWRY-H8aQEDMZDsAk2dajo0pZI0DG8ZO-YZ-ySh4jRDp053uO9335H4EDqjZEoJKS-HNk455fIDmlCiVEGrqj4a-4oVshLqGH2OcU1I1hT_hI7LWrGKVnSCfi90suDTn6fnAE4naLFZ6aBNgmBjsiZiHWNv7Ku0s2mFfe8zPUCIGQBv4DCOKTt5nFYQ9LDHuQXXQnB7PBxORNz1zvU7639i7bGNZgUba_Ji6B_hFH3stIvw5a2eoIeb64fZ92J-d_tj9m1eGMaVLITRrDW6k6VUhqu2I5SIsgJFDOFcdLWElgPntWBAlGgFNQaWksglqUFJdoK-HmyH0P_aQkzNJj8EnNMe-m1sqBSSUUEI-w-U11KVgpcZvfgHXffb4PM_RkOmhJLlaHj-Rm2XG2ibIdiNDvvmbxoZKA7AzjrYv-uUNGPKTU65GVNuFlf3Y2UvHPedlA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1863969823</pqid></control><display><type>article</type><title>Patient‐related characteristics associated with non‐persistence with statin therapy in elderly patients following an ischemic stroke</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Wawruch, Martin ; Zatko, Dusan ; Wimmer, Gejza ; Luha, Jan ; Hricak, Vasil ; Murin, Jan ; Kukumberg, Peter ; Tesar, Tomas ; Hloska, Adam ; Shah, Rashmi</creator><creatorcontrib>Wawruch, Martin ; Zatko, Dusan ; Wimmer, Gejza ; Luha, Jan ; Hricak, Vasil ; Murin, Jan ; Kukumberg, Peter ; Tesar, Tomas ; Hloska, Adam ; Shah, Rashmi</creatorcontrib><description>Purpose This study was aimed at evaluating the extent of non‐persistence with statin therapy in elderly patients after an ischemic stroke and identifying patient‐related characteristics that are risk factors for non‐persistence. Methods The evaluable study cohort (n = 2748) was derived from the database of the largest health insurance provider in the Slovak Republic. Patients aged ≥65 years who were initiated on statin therapy following the diagnosis of an ischemic stroke during one full year (1 January 2010 to 31 December 2010) constituted this cohort. Each patient was followed for a period of 3 years from the date of the first statin prescription. Patients with a continuous treatment gap of 6 months without statin prescription were designated as non‐persistent. The Cox proportional hazard model was applied to determine patient‐associated characteristics that influenced the likelihood of non‐persistence. Results During the 3‐year follow‐up period, 39.7% of patients in the study cohort became non‐persistent. Factors associated with decreased probability of a patient becoming non‐persistent were age ≥75 years (hazard ratio (HR) 0.75), polypharmacy (concurrent use of ≥6 drugs) (HR 0.79), diabetes mellitus (HR 0.80), dementia (HR 0.81) and hypercholesterolemia (HR 0.50). On the other hand, the presence of anxiety disorders (HR 1.33) predicted an increased likelihood of a patient being non‐persistent. Conclusions Our findings suggest that patients aged ≥75 years or those with the presence of diabetes mellitus, dementia, hypercholesterolemia or polypharmacy were likely to be persistent with statin therapy, whereas those with anxiety disorders may need greater assistance with persistence of statin therapy. Copyright © 2016 John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 1053-8569</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/pds.4148</identifier><identifier>PMID: 27935151</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Aged ; Aged, 80 and over ; anxiety disorders ; Anxiety Disorders - epidemiology ; Brain Ischemia - drug therapy ; Cohort Studies ; Dementia ; Diabetes ; diabetes mellitus ; Female ; Follow-Up Studies ; Health risk assessment ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration &amp; dosage ; hypercholesterolemia ; Male ; Medication Adherence - statistics &amp; numerical data ; Patients ; persistence ; Polypharmacy ; Proportional Hazards Models ; Retrospective Studies ; Risk Factors ; Slovakia ; statin ; Statins ; Stroke ; Stroke - drug therapy</subject><ispartof>Pharmacoepidemiology and drug safety, 2017-02, Vol.26 (2), p.201-207</ispartof><rights>Copyright © 2016 John Wiley &amp; Sons, Ltd.</rights><rights>Copyright © 2017 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3498-6ca3dcaf8289c49df010625e90c0446f78ed4e44763e096d61cceb808b07e983</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpds.4148$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpds.4148$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27935151$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wawruch, Martin</creatorcontrib><creatorcontrib>Zatko, Dusan</creatorcontrib><creatorcontrib>Wimmer, Gejza</creatorcontrib><creatorcontrib>Luha, Jan</creatorcontrib><creatorcontrib>Hricak, Vasil</creatorcontrib><creatorcontrib>Murin, Jan</creatorcontrib><creatorcontrib>Kukumberg, Peter</creatorcontrib><creatorcontrib>Tesar, Tomas</creatorcontrib><creatorcontrib>Hloska, Adam</creatorcontrib><creatorcontrib>Shah, Rashmi</creatorcontrib><title>Patient‐related characteristics associated with non‐persistence with statin therapy in elderly patients following an ischemic stroke</title><title>Pharmacoepidemiology and drug safety</title><addtitle>Pharmacoepidemiol Drug Saf</addtitle><description>Purpose This study was aimed at evaluating the extent of non‐persistence with statin therapy in elderly patients after an ischemic stroke and identifying patient‐related characteristics that are risk factors for non‐persistence. Methods The evaluable study cohort (n = 2748) was derived from the database of the largest health insurance provider in the Slovak Republic. Patients aged ≥65 years who were initiated on statin therapy following the diagnosis of an ischemic stroke during one full year (1 January 2010 to 31 December 2010) constituted this cohort. Each patient was followed for a period of 3 years from the date of the first statin prescription. Patients with a continuous treatment gap of 6 months without statin prescription were designated as non‐persistent. The Cox proportional hazard model was applied to determine patient‐associated characteristics that influenced the likelihood of non‐persistence. Results During the 3‐year follow‐up period, 39.7% of patients in the study cohort became non‐persistent. Factors associated with decreased probability of a patient becoming non‐persistent were age ≥75 years (hazard ratio (HR) 0.75), polypharmacy (concurrent use of ≥6 drugs) (HR 0.79), diabetes mellitus (HR 0.80), dementia (HR 0.81) and hypercholesterolemia (HR 0.50). On the other hand, the presence of anxiety disorders (HR 1.33) predicted an increased likelihood of a patient being non‐persistent. Conclusions Our findings suggest that patients aged ≥75 years or those with the presence of diabetes mellitus, dementia, hypercholesterolemia or polypharmacy were likely to be persistent with statin therapy, whereas those with anxiety disorders may need greater assistance with persistence of statin therapy. Copyright © 2016 John Wiley &amp; Sons, Ltd.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>anxiety disorders</subject><subject>Anxiety Disorders - epidemiology</subject><subject>Brain Ischemia - drug therapy</subject><subject>Cohort Studies</subject><subject>Dementia</subject><subject>Diabetes</subject><subject>diabetes mellitus</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration &amp; dosage</subject><subject>hypercholesterolemia</subject><subject>Male</subject><subject>Medication Adherence - statistics &amp; numerical data</subject><subject>Patients</subject><subject>persistence</subject><subject>Polypharmacy</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Slovakia</subject><subject>statin</subject><subject>Statins</subject><subject>Stroke</subject><subject>Stroke - drug therapy</subject><issn>1053-8569</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkb9u2zAQxokiReMmBfIEAYEsXeSQIkWRY-H8aQEDMZDsAk2dajo0pZI0DG8ZO-YZ-ySh4jRDp053uO9335H4EDqjZEoJKS-HNk455fIDmlCiVEGrqj4a-4oVshLqGH2OcU1I1hT_hI7LWrGKVnSCfi90suDTn6fnAE4naLFZ6aBNgmBjsiZiHWNv7Ku0s2mFfe8zPUCIGQBv4DCOKTt5nFYQ9LDHuQXXQnB7PBxORNz1zvU7639i7bGNZgUba_Ji6B_hFH3stIvw5a2eoIeb64fZ92J-d_tj9m1eGMaVLITRrDW6k6VUhqu2I5SIsgJFDOFcdLWElgPntWBAlGgFNQaWksglqUFJdoK-HmyH0P_aQkzNJj8EnNMe-m1sqBSSUUEI-w-U11KVgpcZvfgHXffb4PM_RkOmhJLlaHj-Rm2XG2ibIdiNDvvmbxoZKA7AzjrYv-uUNGPKTU65GVNuFlf3Y2UvHPedlA</recordid><startdate>201702</startdate><enddate>201702</enddate><creator>Wawruch, Martin</creator><creator>Zatko, Dusan</creator><creator>Wimmer, Gejza</creator><creator>Luha, Jan</creator><creator>Hricak, Vasil</creator><creator>Murin, Jan</creator><creator>Kukumberg, Peter</creator><creator>Tesar, Tomas</creator><creator>Hloska, Adam</creator><creator>Shah, Rashmi</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>201702</creationdate><title>Patient‐related characteristics associated with non‐persistence with statin therapy in elderly patients following an ischemic stroke</title><author>Wawruch, Martin ; Zatko, Dusan ; Wimmer, Gejza ; Luha, Jan ; Hricak, Vasil ; Murin, Jan ; Kukumberg, Peter ; Tesar, Tomas ; Hloska, Adam ; Shah, Rashmi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3498-6ca3dcaf8289c49df010625e90c0446f78ed4e44763e096d61cceb808b07e983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>anxiety disorders</topic><topic>Anxiety Disorders - epidemiology</topic><topic>Brain Ischemia - drug therapy</topic><topic>Cohort Studies</topic><topic>Dementia</topic><topic>Diabetes</topic><topic>diabetes mellitus</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration &amp; dosage</topic><topic>hypercholesterolemia</topic><topic>Male</topic><topic>Medication Adherence - statistics &amp; numerical data</topic><topic>Patients</topic><topic>persistence</topic><topic>Polypharmacy</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Slovakia</topic><topic>statin</topic><topic>Statins</topic><topic>Stroke</topic><topic>Stroke - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wawruch, Martin</creatorcontrib><creatorcontrib>Zatko, Dusan</creatorcontrib><creatorcontrib>Wimmer, Gejza</creatorcontrib><creatorcontrib>Luha, Jan</creatorcontrib><creatorcontrib>Hricak, Vasil</creatorcontrib><creatorcontrib>Murin, Jan</creatorcontrib><creatorcontrib>Kukumberg, Peter</creatorcontrib><creatorcontrib>Tesar, Tomas</creatorcontrib><creatorcontrib>Hloska, Adam</creatorcontrib><creatorcontrib>Shah, Rashmi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wawruch, Martin</au><au>Zatko, Dusan</au><au>Wimmer, Gejza</au><au>Luha, Jan</au><au>Hricak, Vasil</au><au>Murin, Jan</au><au>Kukumberg, Peter</au><au>Tesar, Tomas</au><au>Hloska, Adam</au><au>Shah, Rashmi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patient‐related characteristics associated with non‐persistence with statin therapy in elderly patients following an ischemic stroke</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><addtitle>Pharmacoepidemiol Drug Saf</addtitle><date>2017-02</date><risdate>2017</risdate><volume>26</volume><issue>2</issue><spage>201</spage><epage>207</epage><pages>201-207</pages><issn>1053-8569</issn><eissn>1099-1557</eissn><abstract>Purpose This study was aimed at evaluating the extent of non‐persistence with statin therapy in elderly patients after an ischemic stroke and identifying patient‐related characteristics that are risk factors for non‐persistence. Methods The evaluable study cohort (n = 2748) was derived from the database of the largest health insurance provider in the Slovak Republic. Patients aged ≥65 years who were initiated on statin therapy following the diagnosis of an ischemic stroke during one full year (1 January 2010 to 31 December 2010) constituted this cohort. Each patient was followed for a period of 3 years from the date of the first statin prescription. Patients with a continuous treatment gap of 6 months without statin prescription were designated as non‐persistent. The Cox proportional hazard model was applied to determine patient‐associated characteristics that influenced the likelihood of non‐persistence. Results During the 3‐year follow‐up period, 39.7% of patients in the study cohort became non‐persistent. Factors associated with decreased probability of a patient becoming non‐persistent were age ≥75 years (hazard ratio (HR) 0.75), polypharmacy (concurrent use of ≥6 drugs) (HR 0.79), diabetes mellitus (HR 0.80), dementia (HR 0.81) and hypercholesterolemia (HR 0.50). On the other hand, the presence of anxiety disorders (HR 1.33) predicted an increased likelihood of a patient being non‐persistent. Conclusions Our findings suggest that patients aged ≥75 years or those with the presence of diabetes mellitus, dementia, hypercholesterolemia or polypharmacy were likely to be persistent with statin therapy, whereas those with anxiety disorders may need greater assistance with persistence of statin therapy. Copyright © 2016 John Wiley &amp; Sons, Ltd.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>27935151</pmid><doi>10.1002/pds.4148</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1053-8569
ispartof Pharmacoepidemiology and drug safety, 2017-02, Vol.26 (2), p.201-207
issn 1053-8569
1099-1557
language eng
recordid cdi_proquest_miscellaneous_1868316003
source MEDLINE; Access via Wiley Online Library
subjects Aged
Aged, 80 and over
anxiety disorders
Anxiety Disorders - epidemiology
Brain Ischemia - drug therapy
Cohort Studies
Dementia
Diabetes
diabetes mellitus
Female
Follow-Up Studies
Health risk assessment
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
hypercholesterolemia
Male
Medication Adherence - statistics & numerical data
Patients
persistence
Polypharmacy
Proportional Hazards Models
Retrospective Studies
Risk Factors
Slovakia
statin
Statins
Stroke
Stroke - drug therapy
title Patient‐related characteristics associated with non‐persistence with statin therapy in elderly patients following an ischemic stroke
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T17%3A46%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patient%E2%80%90related%20characteristics%20associated%20with%20non%E2%80%90persistence%20with%20statin%20therapy%20in%20elderly%20patients%20following%20an%20ischemic%20stroke&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Wawruch,%20Martin&rft.date=2017-02&rft.volume=26&rft.issue=2&rft.spage=201&rft.epage=207&rft.pages=201-207&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/pds.4148&rft_dat=%3Cproquest_pubme%3E1847892642%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1863969823&rft_id=info:pmid/27935151&rfr_iscdi=true